Uppsala 2nd January 2019


Nanexa’s PharmaShell® patent approved in the United States

The US Patent Office has approved Nanexa’s patent application for the drug delivery platform PharmaShell®.

Nanexa has developed a drug delivery system – PharmaShell® – for parenteral drug administration. PharmaShell® enables drug release over a longer period of time, from a few weeks to really long depot times of up to one year. Depot time can, through adjustments in the manufacturing process of PharmaShell®, be controlled to the desired length.

PharmaShells® properties, with extremely high drug load and the ability to control the initial release, makes it unique in the market. The aforementioned properties are also in demand by the industry to create new and more effective drugs with the possibility of limiting the side effects of the drug.

The US Patent Office has approved Nanexa’s patent application on January 1, 2019. The now approved patent covers the product PharmaShell® itself as well as the method for its manufacture and formulations of PharmaShell® coated drugs. The approved patent has patent number US 10166198.


The company’s CEO David Westberg comments:

It is with great satisfaction that I can now confirm that the PharmaShell® patent is approved in the USA. We have always felt safe in our patent situation, but it still means a lot to get it confirmed by the US Patent Office. The United States is our largest market and now that we have an approved patent, we end up in a more interesting position in discussions with potential partners.

The path from filing a patent application to an approved patent is long and I am glad that we this spring made the decision to speed up the process by following the so-called “Track 1” routine at the US Patent Office. The fact that we took the initiative for a personal interview with the reviewer in the US probably also meant a lot to speed up the approval process.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.